For patients who have heparin-induced thrombocytopenia, which of the following medications might be given?

In patients who have heparin-induced thrombocytopenia (HIT), the preferred treatment often includes a direct thrombin inhibitor, which is where Angiomax (bivalirudin) comes in. Angiomax is specifically designed to provide effective anticoagulation by directly inhibiting thrombin, thus decreasing the risk of clot formation without the complications associated with heparin. Since patients with HIT exhibit a paradoxical increase in thrombosis, using a medication like Angiomax is advantageous for both managing and preventing further clotting events.

Other medications listed serve different purposes. Plavix is an antiplatelet medication that does not directly address the issue of thrombosis in the context of HIT. Diltiazem is primarily a calcium channel blocker used for hypertension and cardiac conditions and does not play a role in the management of HIT. Magnesium sulfate, while it can be used for various medical conditions, particularly in obstetrics, does not function as an anticoagulant and would not be appropriate in this context.

Thus, Angiomax is specifically suited to the unique challenges presented by heparin-induced thrombocytopenia, making it the correct choice for patients affected by this condition.